MedTrace Logo

Modified Measles Virus (MV-NIS) for Children and Young Adults With Recurrent Medulloblastoma or Recurrent ATRT

NCT02962167 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2024-03-20

No results posted yet for this study

Summary

This is a three arm Phase I study within the Pacific Pediatric Neuro-Oncology Consortium (PNOC).

This study will look to determine the safety and recommended phase 2 dose of the modified measles virus (MV-NIS) in children and young adults with recurrent medulloblastoma or atypical teratoid rhabdoid tumor (ATRT).

Conditions

  • Medulloblastoma, Childhood, Recurrent
  • Atypical Teratoid/Rhabdoid Tumor
  • Medulloblastoma Recurrent

Interventions

BIOLOGICAL

Modified Measles Virus

Administration of MV-NIS either into the tumor bed, if surgery to remove local tumor

BIOLOGICAL

Modified Measles Virus Lumbar Puncture

Administration of MV-NIS into the cerebrospinal fluid via lumbar puncture

Sponsors & Collaborators

  • No More Kids With Cancer

    collaborator UNKNOWN

  • The Matthew Larson Foundation for Pediatric Brain Tumors

    collaborator OTHER

  • Vyriad, Inc.

    collaborator INDUSTRY

  • Mayo Clinic

    collaborator OTHER

  • Sabine Mueller, MD, PhD

    lead OTHER

Principal Investigators

  • Sabine Mueller, MD, PhD, MAS · University of California, San Francisco

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
12 Months
Max Age
39 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-02-22
Primary Completion
2023-05-10
Completion
2023-05-10
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02962167 on ClinicalTrials.gov